Verastem Oncology Reports Strong Launch of AVMAPKI FAKZYNJA CO-PACK Amid Pipeline Advances
Event summary
- Verastem Oncology reported $30.9 million in net product revenues for 2025 from AVMAPKI FAKZYNJA CO-PACK, following its FDA approval in May 2025.
- VS-7375, the company's oral KRAS G12D (ON/OFF) inhibitor, cleared multiple dose levels in Phase 1/2 trials with no dose-limiting toxicities.
- GenFleet Therapeutics received Breakthrough Therapy Designation in China for VS-7375 (GFH375) in KRAS G12D-mutated NSCLC.
- Verastem completed a $96.9 million public offering of common stock and pre-funded warrants in November 2025.
The big picture
Verastem Oncology's 2025 performance highlights its transition from a development-stage biotech to a commercial entity, with the successful launch of AVMAPKI FAKZYNJA CO-PACK. The company's pipeline, particularly VS-7375, positions it competitively in the KRAS inhibitor space, though it faces regulatory and commercial execution challenges. The $96.9 million funding round provides a cash runway into 2027, supporting both commercial and R&D initiatives.
What we're watching
- Commercial Execution
- Whether Verastem can sustain the strong launch momentum of AVMAPKI FAKZYNJA CO-PACK and expand its market share in KRAS-mutated recurrent LGSOC.
- Pipeline Progress
- The pace at which VS-7375 advances through Phase 1/2 trials and the potential for regulatory approvals in key indications like pancreatic and lung cancer.
- Regulatory Strategy
- How Verastem navigates the NCCN guidelines update and secures broader approvals for AVMAPKI FAKZYNJA CO-PACK in Europe and Japan.
Related topics